Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7115886 | 0.91 | CYP17A1 (0.45) | CYP17A1PTGS2NR1H2NR1H3RPS6KA3 | |
| SCHEMBL6736152 | 0.89 | NR1H2 (0.46) | S1PR1CYP17A1PTGS2NR1H2NR1H3 | |
| SCHEMBL6728875 | 0.89 | S1PR1 (0.47) | S1PR1CYP17A1PTGS2NR1H2NR1H3 | |
| SCHEMBL7170268 | 0.88 | PTGS2 (0.50) | CYP17A1PTGS2RPS6KA3ALOX5APFEN1 | |
| SCHEMBL7108675 | 0.87 | PTGS2 (0.49) | CYP17A1PTGS2RPS6KA3SLC22A12 | |
| SCHEMBL7111106 | 0.85 | SLC22A12 (0.54) | PTGS2NR1H2NR1H3RPS6KA3ALOX5AP | |
| SCHEMBL7114909 | 0.84 | PTGS2 (0.49) | CYP17A1PTGS2RPS6KA3SLC22A12 | |
| SCHEMBL7114859 | 0.84 | PTGS2 (0.52) | CYP17A1PTGS2RPS6KA3SLC22A12 | |
| SCHEMBL7109862 | 0.84 | PTGS2 (0.46) | CYP17A1PTGS2RPS6KA3ALOX5APFEN1 | |
| SCHEMBL7047515 | 0.84 | PTGS2 (0.42) | CYP17A1PTGS2NR1H2NR1H3RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | S1PR1 199/4885CYP17A1 959/4885PTGS2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.